Dravet syndrome is one of the most severe and devastating forms of epilepsy a child can face. It causes frequent, hard-to-control seizures and long-term neurodevelopmental impairment that affects cognition, behavior, and quality of life for both the child and their family. For years, treatment options have been extremely limited and largely inadequate.
Now, a landmark international clinical trial led by researchers at University College London and Great Ormond Street Hospital has identified a potentially life-changing treatment. The results, published in the New England Journal of Medicine, show that an experimental epilepsy drug called zorevunersen reduces seizures by up to 91 percent in children with Dravet syndrome, offering renewed hope for families who have long been waiting for a meaningful breakthrough.
What Is Dravet Syndrome?
Dravet syndrome is a rare genetic condition that typically begins in the first year of life. It is caused by a mutation in one copy of the SCN1A gene, which prevents the body from producing enough of a protein essential for proper nerve cell signaling. Without adequate levels of this protein, the brain’s electrical activity becomes unstable, leading to frequent and often prolonged seizures.
Beyond seizures, the condition has a profound impact on the lives of affected children and their families. It impairs cognitive development, limits motor skills, and creates significant behavioral challenges. Most existing medications only partially control the seizures and do very little to address the broader developmental effects of the disease.
How Zorevunersen Works
Developed by Stoke Therapeutics in collaboration with Biogen, zorevunersen takes a fundamentally different approach to treating Dravet syndrome. Rather than simply suppressing seizure activity, the drug targets the root cause of the condition by increasing protein production from the healthy copy of the SCN1A gene.
The medication is delivered directly into the central nervous system through a lumbar puncture, allowing it to reach the brain where it is needed most. During the initial zorevunersen clinical trials, children received up to 70 milligrams of the drug, either as a single dose or with additional doses two or three months later over a six-month period.
What the Clinical Trial Found
The trial involved 81 children with Dravet syndrome, and participants were patients at UK hospitals including Great Ormond Street Hospital, Sheffield Children’s Hospital, Evelina London Children’s Hospital, and The Royal Hospital for Children in Glasgow. Research was led by Professor Helen Cross, Director and Professor of Childhood Epilepsy at the UCL Great Ormond Street Institute of Child Health.
Before starting treatment, these children experienced an average of 17 seizures per month. The results were remarkable. Children who received regular doses of zorevunersen experienced seizure reductions ranging from 59 to 91 percent across different monitoring intervals during the first 20 months of the extension study.
Critically, the benefits extended well beyond seizure control. Over a three-year period, children showed measurable improvements in overall clinical status, cognition, behavior, and quality of life. This marks the first time a treatment for Dravet syndrome has demonstrated the potential for genuine disease modification rather than simply symptom management.
Professor Helen Cross described the significance of these findings by noting how difficult it is to see patients with hard-to-treat genetic epilepsies with impacts that go beyond seizures, and how it is heartbreaking when treatment options are limited. These results offer the kind of meaningful progress that families have been desperately hoping for.
What Families and Advocates Are Saying
Galia Wilson, Dravet Syndrome UK Chair of Trustees, expressed strong support for the findings. She highlighted that the charity regularly sees the devastating impact this condition has on families, and that they are thrilled about the latest results from the initial zorevunersen clinical trials. For many families, the possibility that their children could lead much healthier and happier lives feels closer than ever before.
What Comes Next
The safety profile of zorevunersen has been encouraging. Most side effects were mild, though elevated cerebrospinal fluid protein levels were observed in some participants during the extension study. One patient discontinued treatment due to this side effect.
Stoke Therapeutics is now moving forward with the Phase 3 EMPEROR Study, which aims to enroll approximately 150 patients across the United States, the United Kingdom, and Japan. Enrollment is expected to be completed by mid-2026, with data readout projected for mid-2027 to support a potential regulatory application.
How Current Blood Tests for Cancer Work
To appreciate what makes this new technology significant, it helps to understand how existing blood tests contribute to cancer diagnosis. When a doctor suspects cancer based on a patient’s symptoms or medical history, they may order specific tests to look for indicators in the blood. A tumor marker test, for example, measures substances that certain types of cancer produce or trigger the body to produce. Prostate-specific antigen is one of the most well-known tumor markers, used widely in prostate cancer screening. Other test types look for circulating tumor cells, tumor DNA fragments shed into the bloodstream, or unusual patterns in protein levels that may suggest the presence of disease.
In recent years, the multi-cancer early detection MCED test has emerged as a promising advance. These tests analyze blood samples for molecular signals associated with dozens of cancer types, enabling broad cancer screening from a single draw. However, most current approaches still require chemical amplification to boost tiny molecular signals to detectable levels. This amplification adds time, complexity, cost, and the potential for errors in the test result. Even with these tools, many cancers are still not caught until later stages, when the disease is harder to treat.
The challenge is sensitivity. Detecting a handful of cancer-related molecules among billions of normal molecules in a blood sample is an extraordinary technical problem. Any blood test for cancer that aims to detect cancer at its earliest stages needs to achieve levels of sensitivity that push the boundaries of current technology.
A New Approach Using Light, CRISPR, and Quantum Dots
The Shenzhen University team addressed this challenge by combining three cutting-edge technologies into a single detection platform. At the heart of their sensor is a process called second harmonic generation, a phenomenon in which incoming light interacts with a specially designed material and is converted to light at half the original wavelength. The material they chose is molybdenum disulfide, a two-dimensional semiconductor that produces a clean optical signal with very little background noise.
To amplify this signal without the chemical amplification steps that slow down conventional blood tests, the researchers attached tiny quantum dots to the sensor surface using self-assembled DNA structures shaped like miniature pyramids. These DNA tetrahedra hold each quantum dot at a precise distance from the sensor surface, enhancing the local optical field and strengthening the light signal.
The detection mechanism relies on CRISPR gene-editing technology. Specifically, the team used a protein called Cas12a that is programmed to recognize a specific cancer biomarker. When the target biomarker is present in the blood sample, Cas12a is activated and cleaves the DNA structures that hold the quantum dots in place. As the quantum dots are released, the light signal drops in a measurable, proportional manner. The greater the biomarker concentration, the larger the signal change. Because the baseline signal is low-noise, even a small number of target molecules yields a clear, readable result.
What the Research Found
The researchers chose to target miR-21, a microRNA strongly associated with lung cancer and one of the most studied biomarkers in oncology. Their sensor detected cancer at sub-attomolar concentrations, enabling it to identify miR-21 even when only a few molecules were present in the sample. This level of sensitivity far exceeds that of most conventional blood tests.
Critically, the test detected miR-21 not only in controlled laboratory solutions but also in human serum samples taken from lung cancer patients. This step is important because human blood is a complex mixture of proteins, cells, and other substances that can interfere with detection. The fact that the sensor performed reliably in real patient samples suggests it has practical potential beyond the laboratory. The test also demonstrated high specificity, successfully distinguishing the target microRNA from similar RNA strands that might otherwise produce false results.
The researchers noted that their platform is programmable, meaning the CRISPR component can be adjusted to target different biomarkers. This flexibility opens the door to detecting markers associated with breast cancer, prostate cancer, and potentially many other types of cancer, as well as non-cancer conditions. The same technology could, in theory, be adapted to identify viruses, bacteria, or environmental toxins, making it a versatile tool that extends well beyond oncology.
What This Means for Cancer Screening
The potential implications for cancer screening are considerable. If further development confirms these early results, this type of sensor could eventually be used as a frontline screening tool in clinics and hospitals, catching molecular signals of disease before conventional imaging or standard blood tests would register anything unusual. For patients, that could mean earlier diagnosis, more treatment options, and better outcomes.
The research team has stated that their next priority is to miniaturize the optical equipment so the sensor can function as a portable device. Their goal is a bedside or clinic-ready tool that could be used not only in major hospitals but also in low-resource or remote settings where access to advanced imaging and clinical laboratory improvement certified facilities may be limited. Such a device could be particularly meaningful in communities where cancer screening rates are low and late-stage diagnosis is common.
It is worth noting that this technology is still in its early stages. The study demonstrates proof of concept, not a finished product. Clinical trials, regulatory approval, and large-scale validation will all be necessary before this kind of blood test for cancer reaches routine medical practice. But the underlying science is sound, and the results are promising enough to warrant serious attention.
Positive Takeaway
For families living with Dravet syndrome, this research represents something that has been in short supply for far too long: real hope. The fact that zorevunersen not only reduces seizures but also appears to improve cognitive and behavioral outcomes suggests a future where children with this condition may finally have access to a treatment that addresses the full scope of their needs. As clinical trials continue, the path toward approval grows clearer, and with it, the possibility of transforming lives.
Sources
- New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2506295
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41780062/
- UCL News: https://www.ucl.ac.uk/news/2026/mar/life-changing-drug-identified-children-rare-epilepsy
- Stoke Therapeutics: https://investor.stoketherapeutics.com/news-releases/news-release-details/new-england-journal-medicine-publishes-first-data-demonstrate
Disclaimer: This article is for informational purposes only and is based on publicly available research. It does not constitute medical advice. Always consult a qualified healthcare professional for medical guidance.
